Vasculitis
87
23
26
43
Key Insights
Highlights
Success Rate
93% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
3.4%
3 terminated out of 87 trials
93.5%
+6.9% vs benchmark
10%
9 trials in Phase 3/4
16%
7 of 43 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 43 completed trials
Clinical Trials (87)
JOint Use of Database to Identify Risk Factors of CARDio-vascular Toxicity Induced by Immune Checkpoint Inhibitors
Mass Spectrometry-based Immune Profiling in Autoimmune Diseases
Pain-Sleep in Rheumatic Disease
Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.
Ocular Manifestations of Granulomatosis With Polyangiitis.
Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms
SysteMic vAsculitis pRognosis and ouTcome
The RheumSafer Study: Improving Medication Appropriateness in People With Rheumatic Conditions
Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting
Pregnancy and Medically Assisted Conception in Rare Diseases
Clinico-biological Collection to Investigate the Physiopathology of Systemic Autoimmune Diseases
Vasculitis Pregnancy Registry
Longitudinal Study for Relapsing Polychondritis
Longitudinal Study for Central Nervous System Vasculitis
Clinical Transcriptomics in Systemic Vasculitis (CUTIS)
Generative AI Impact on Rheumatoid Arthritis Complications Diagnosis
Vascular Lab Resource (VLR) Biorepository
MEMRI and Kidney Disease
Prospective Longitudinal Cohort Study of Vasculitis Patients
FDG Digital PET/CT as First Line Investigation for Giant Cell Arteritis